Infectious Disease
Hepatitis B
168
Pipeline Programs↗
41
Active Trials↗
41
Companies Involved↗
Hepatitis B is a highly competitive landscape with 168 programs across 41 companies. The most active players are Boehringer Ingelheim, Novira Therapeutics, Inc., Takeda. 43 therapies are approved with 37 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical25
Phase 122
Phase 241
Phase 337
Analysis
Modality Breakdown
177programs
Small molecule10358%
Vaccine6436%
Cell therapy42%
Protein / enzyme21%
Peptide21%
Monoclonal antibody11%
RNA therapy11%
Modality classified for 100% of 253 pipeline programs.
Analysis
Trial Status
296
clinical trials
Completed182 · 61%
Unknown status57 · 19%
Recruiting16 · 5%
Not yet recruiting12 · 4%
Terminated10 · 3%
Active, not recruiting10 · 3%
Other9 · 3%
Clinical Trials
Trial Activity
296 trials
Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D
Recruiting·—·N/A·NCT07491848·25 enrolled
Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody (The SAMBA Study)
Recruiting·—·Phase 1·NCT06668727·30 enrolled
Page 1 of 20
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)